Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report)'s share price was up 11.3% during trading on Friday . The company traded as high as $0.70 and last traded at $0.63. Approximately 151,239,068 shares traded hands during mid-day trading, an increase of 431% from the average daily volume of 28,475,689 shares. The stock had previously closed at $0.57.
Analysts Set New Price Targets
Separately, StockNews.com initiated coverage on Tonix Pharmaceuticals in a report on Sunday, December 15th. They issued a "sell" rating on the stock.
Get Our Latest Stock Report on Tonix Pharmaceuticals
Tonix Pharmaceuticals Stock Performance
The stock has a market cap of $114.30 million, a price-to-earnings ratio of -0.01 and a beta of 2.23. The company's fifty day simple moving average is $0.19 and its two-hundred day simple moving average is $0.52. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($2.03) by $1.80. The company had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. On average, analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.
About Tonix Pharmaceuticals
(
Get Free Report)
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Featured Stories
Before you consider Tonix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.
While Tonix Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
